Eye Imaging to Study Photoreceptor Damage in Geographic Atrophy
Tests whether combined eye scans link retina changes to vision in geographic atrophy.
Plain-language title generated from the registry record
Registry title: Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study
Key facts
- Where
- Madison, United StatesSee the site
Where in United States
- University of WisconsinMadison, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Wisconsin, Madison
- Trial code
- NCT07747662
- Record updated
- 26 October 2026
- Original description
This research sub-study is to evaluate if combining images from Optical Coherence Tomography (OCT) scans with Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) could show a link between structural changes in the back of the eye and vision. 10 participants that were enrolled in the COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy study [NCT05961332] will be approached to enroll. Participants may complete OCT imaging and initial assessments during an initial visit and may return for additional procedures, including microperimetry and AOSLO imaging, within a window of up to 4 weeks.Read full original descriptionShow less
Structure and Function in the Progression of Atrophic AMD: Validation of Photoreceptor Damage Observed With OCT Using AOSLO (Adaptive Optics Scanning Light Ophthalmoscopy and Microperimetry
This research sub-study is to evaluate if combining images from Optical Coherence Tomography (OCT) scans with Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) could show a link between structural changes in the back of the eye and vision. 10 participants that were enrolled in the COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy study [NCT05961332] will be approached to enroll. Participants may complete OCT imaging and initial assessments during an initial visit and may return for additional procedures, including microperimetry and AOSLO imaging, within a window of up to 4 weeks.
Inclusion: 50 years or older and may be either male or female and may be of any race; Established diagnosis of geographic atrophy (GA) due to age-related macular degeneration (AMD); GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude participants from participation; Willing to participate as evidenced by signing the written informed consent; Additional Sub-study Inclusion Criteria:; Early-stage GA defined as; GA area of between 1.25 mm2 and 23 mm2; GA may be unifocal or multifocal; GA may be subfoveal or extrafoveal; Concurrent peripapillary atrophy will not exclude participant from participation; Phakic and pseudophakic participants are eligible for enrollment, with phakic participants prioritized when feasible.
Exclusion: Presence of concurrent retinal disease which may confound assessment; Additional Sub-study Exclusion Criteria:; Prior or current treatment with intraocular injections for geographic atrophy (e.g., pegcetacoplan [Syfovre] or similar therapies) is not permitted; Ocular media opacity or other condition(s) that, in the opinion of the investigators, may preclude imaging; Unable to tolerate ophthalmic imaging; Presence of neovascular AMD on optical coherence tomography (OCT) as confirmed by an ophthalmologist; Presence of significant media opacity preventing adequate retinal imaging; Individuals who, in the opinion of the investigator, are unable to tolerate study procedures or comply with study requirements.